logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. Fulltext. Treating hyperlipidemia for the primary prevention of coronary disease : Are higher dosages of lovastatin cost-effective ?

    Article - En anglais

    Fulltext.

    Objective 

    To compare the average and marginal lifetime cost-effectiveness of increasing dosages of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, such as lovastatin, for the primary prevention of coronary heart disease (CHD).

    Methods 

    We estimated the lifelong costs and benefits of the modification of lipid levels achieved with lovastatin based on published studies and a validated CHD prevention computer model.

    Patients were middle-aged men and women without CHD, with mean total serum cholesterol levels of 6.67,7.84, and 9.90 mmol/L (258,303, and 383 mg/dL), and high-density lipoprotein cholesterol levels of 1.19 mmol/L (46 mg/dL), as described in clinical trials.

    We estimated the cost per year of life saved for dosages of lovastatin ranging from 20 to 80 mg/d that reduced the total cholesterol level between 17% and 34%, and increased high-density lipoprotein cholesterol level between 4% and 13%. Results : After discounting benefits and costs by 5% annually, the average cost-effectiveness of lovastatin, 20 mg/d, ranged from $11 040 to $52 463 for men and women.

    The marginal cost-effectiveness of 40 mg/d vs 20 mg/d remained in this range ($25 711 to $60 778) only for persons with baseline total cholesterol levels of 7.84 mmol/L (303 mg/dL) or higher. (...)

    Mots-clés Pascal : Lovastatine, Chimiothérapie, Inhibiteur enzyme, Hydroxymethylglutaryl-CoA reductase, Oxidoreductases, Enzyme, Hypolipémiant, Traitement, Hyperlipémie, Cardiopathie coronaire, Prévention, Analyse coût efficacité, Economie santé, Homme, Lipide, Métabolisme pathologie, Dyslipémie, Appareil circulatoire pathologie

    Mots-clés Pascal anglais : Lovastatin, Chemotherapy, Enzyme inhibitor, Hydroxymethylglutaryl-CoA reductase, Oxidoreductases, Enzyme, Antilipemic agent, Treatment, Hyperlipemia, Coronary heart disease, Prevention, Cost efficiency analysis, Health economy, Human, Lipids, Metabolic diseases, Dyslipemia, Cardiovascular disease

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 98-0154833

    Code Inist : 002B02N. Création : 21/07/1998.